Transaction · 0001612842-26-000011

Wagner Paul A.

Wagner Paul A., SR, reported a transaction classified as return at Forte Biosciences, Inc. involving 16866.000000 shares. Reported holdings after the transaction were 0.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

returnSEC transaction code DSR
FBRXForte Biosciences, Inc.
Trade date
Aug 27, 2026
Filing date
Aug 27, 2026
View on SEC Insider profile
Estimated value—Shares × reported price
Shares traded16.8kPrice unknown
Holdings after0Direct
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

FBRX price since this filing

Daily closing prices, with the filing date and available return windows
FBRX · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -0.4%1w ago -0.1%1d ago +0.0%
Returns since7d +0.0%30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
return
Code D
Identifier
0001612842-26-000011
Stock Option (right to buy)
Transaction date
Aug 27, 2026
Filed Aug 27, 2026, 08:28 PM · 0d delay
Shares
16,866 sh
Price unknown
Estimated value
—
Computed from shares × price
Holdings after
0 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership
Filing-only score

-14 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 0

    Filing reported within two business days of the transaction.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
  • missing_price-8 points

    price_cents is null

    Missing price reduces confidence in value-based signals.
Missing facts
  • price_cents
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

SEE REMARKS

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly…

  2. F2

    Pursuant to the Merger Agreement, each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that…

  3. F3

    Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock.

  4. F4

    Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to an…

Original filing · 0001612842-26-000011
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

FBRX